Urinary Angiogenin as a Marker for Bladder Cancer: A Meta-Analysis

Amir Hossein Aalami; Hossein Abdeahad; Mohammad Mesgari; Thozhukat Sathyapalan; Amirhossein Sahebkar

doi:10.1155/2021/5557309

Urinary Angiogenin as a Marker for Bladder Cancer: A Meta-Analysis

Biomed Res Int. 2021 Apr 27:2021:5557309. doi: 10.1155/2021/5557309. eCollection 2021.

Authors

Amir Hossein Aalami¹, Hossein Abdeahad², Mohammad Mesgari³, Thozhukat Sathyapalan⁴, Amirhossein Sahebkar^{5

6

7}

Affiliations

¹ Department of Biology, Mashhad Branch, Islamic Azad University, Mashhad, Iran.
² Department of Nutrition and Integrative Physiology, Collogue of Health, University of Utah, Salt Lake City, UT, USA.
³ Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad 9177948974, Iran.
⁴ Academic Diabetes, Endocrinology and Metabolism, Hull York Medical School, University of Hull, UK.
⁵ Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
⁶ Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
⁷ School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.

Abstract

Aims: Bladder cancer (BCa) is a common cancer in North America and Europe that carries considerable morbidity and mortality. A reliable biomarker for early detection of the bladder is crucial for improving the prognosis of BCA. In this meta-analysis, we examine the diagnostic role of the angiogenin (ANG) protein in patients' urine with bladder neoplasm.

Methods: We performed a systematic literature search using ScienceDirect, Web of Science, PubMed/MEDLINE, Scopus, Google Scholar, and Embase, up to 10^th October 2020 databases. Meta-Disc V.1.4 and Comprehensive Meta-Analysis V.2.2 software calculated the pooled specificity, sensitivity, area under the curve (AUC), diagnostic odds ratio (DOR), positive likelihood ratio (LR⁺), negative likelihood ratio (LR^-), Q ^∗ index, and summary receiver-operating characteristic (SROC) for the role of ANG as a urinary biomarker for BCa patients.

Results: Four case-control studies were included with 656 participants (417 cases and 239 controls) in this meta-analysis. The pooled sensitivity of 0.71 (95% CI: 0.66-0.75), specificity of 0.78 (95% CI: 0.73-0.81), LR⁺ of 3.34 (95% CI: 2.02-5.53), LR^- of 0.37 (95% CI: 0.32-0.44), DOR of 9.99 (95% CI: 4.69-21.28), and AUC of 0.789 and Q ^∗ index of 0.726 demonstrate acceptable diagnostic precision of ANG in identifying BCa.

Conclusion: This meta-analysis showed that ANG could be a fair biomarker for the diagnosis of BCa patients.

Publication types

Meta-Analysis
Systematic Review
Retracted Publication

MeSH terms

Biomarkers, Tumor / urine*
Humans
Ribonuclease, Pancreatic / urine*
Sensitivity and Specificity
Urinary Bladder Neoplasms / diagnosis*
Urinary Bladder Neoplasms / urine

Substances

Biomarkers, Tumor
angiogenin
Ribonuclease, Pancreatic